---
document_datetime: 2025-05-23 18:58:23
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/remsima-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: remsima-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.294058
conversion_datetime: 2025-12-20 16:05:07.423666
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Remsima

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 23/05/2025                          |                                             | SmPC,                            | To update sections 4.4 and 4.8 of the SmPC and |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000267792                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.4 and 4.8 of the SmPC and section 4 of the Package Leaflet in order to add post-procedural complications (including infectious and non- infectious complications) to the list of adverse drug reactions (ADRs) with frequency not known and update treatment recommendations for patients with a planned surgical procedure based on a cumulative review of literature, clinical trial and registry data following assessment of the same change for the reference product Remicade. In addition, the MAH took the opportunity to implement other editorial changes to correct for grammatical and/or typographical errors across the PI in EN, DE and IT. Language-specific editorial changes made in the PI of the reference product Remicade that were equally applicable to Remsima have been implemented   |            | Labelling and PL   | section 4 of the Package Leaflet in order to add post-procedural complications (including infectious and non-infectious complications) to the list of adverse drug reactions (ADRs) with frequency not known and update treatment recommendations for patients with a planned surgical procedure based on a cumulative review of literature, clinical trial and registry data following assessment of the same change for the reference product Remicade.   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000268907 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/05/2025 |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                       | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non- significant in-process test - Refused B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non- significant in-process test - Refused   |            |     |                 |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IB / EMA/VR/0000256124 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted                                                                                                                                                               | 19/03/2025 | N/A |                 |
| Variation type IA / EMA/VR/0000253465 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                   | 03/03/2025 |     | Annex II and PL |
| Variation type IB / EMA/VR/0000245253 | This was an application for a group of variations. B.II.b) Manufacture - B.II.b.z Other variation - Accepted                                                                                                                                                                                                                                        | 17/02/2025 | N/A |                 |

<div style=\"page-break-after: always\"></div>

| A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|